Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Sanofi Partners With US Army To Push Zika Vaccine Into Clinical Trials

XTALKS VITALS NEWS

Vaccine

Sanofi is pushing to develop the world’s first Zika vaccine to both provide for the global health crisis, and further strengthen the company’s vaccine portfolio.

Tweetables from this article:

Tweet: The WRAIR will conduct Phase I clinical trial of #Zika vaccine candidate http://ctt.ec/v9UH8+The WRAIR will conduct Phase I clinical trial of Zika vaccine candidate.

Tweet: Sanofi partners with Walter Reed Army Institute of Research for #Zika vaccine http://ctt.ec/ffd3d+Sanofi partners with Walter Reed Army Institute of Research for Zika vaccine.

Share this!

July 7, 2016 | by Sarah Massey, M.Sc.

Global vaccines company Sanofi Pasteur has announced a partnership with the U.S. Army's Walter Reed Army Institute of Research (WRAIR) to co-develop a Zika vaccine candidate. The WRAIR has agreed to transfer its vaccine technology using a purified, inactivated form of the Zika virus, to Sanofi.

In collaboration with multiple government health agencies, the WRAIR will conduct Phase I clinical trials of their Zika vaccine candidate. In return, Sanofi will take responsibility of further development of the vaccine, including conducting Phase II clinical trials, establishing a clinical and regulatory strategy, optimizing production yields and characterizing the vaccine.

Sanofi is just one of multiple companies – including Inovio Pharmaceuticals, GeoVax and Bharat Biotech – in the race to develop a Zika vaccine. Sanofi is pushing to develop the world’s first Zika vaccine to both provide for the global health crisis, and further strengthen the company’s vaccine portfolio.

“We’re looking at this from both a short- and long-term perspective, collaborating to get into the clinic quicker to provide a vaccine in response to the current emergency, and adapting our own technology to ensure production capacity of a vaccine for years to come,” said David Loew, Executive VP and Head of Sanofi Pasteur, in a statement.



According to results from preclinical trials of the WRAIR-developed Zika vaccine – published in the journal, Nature – the candidate showed 100 percent protection against the Zika virus in mice. The authors of the study went on to say that based on these results, “the development of a [Zika] vaccine for humans will likely be readily achievable.”

In addition to the vaccine technology acquired from WRAIR, Sanofi is also leveraging their own platforms to develop a potential Zika vaccine. Sanofi won regulatory approval in late 2015 for its dengue vaccine, which the company hopes might also apply to Zika. The same surface-molecule technology has the potential to work for dengue, Zika and yellow fever, as all three viruses belong to the same flavivirus family.

“In addition to exploring our own vaccine technology used in our new dengue fever vaccine, we are looking at other pathways to get a Zika vaccine into the clinic as soon as possible,” said Loew. “Therefore, this exciting collaboration with the WRAIR creates the opportunity to rapidly move forward.”

So far, Sanofi’s own Zika candidate has not progressed into clinical trials, so it’s possible that they won’t be the first to get a vaccine approval. Last month, competitor company Inovio announced that their Zika vaccine candidate would be entering a Phase I clinical trial in a matter of weeks.


Keywords: Zika, Vaccine, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.